Work

Robustness Assessment of Oncology Dose-Finding Trials Using the Modified Fragility Index

Year: 2024

Type: article

Abstract: OBJECTIVES: The sample sizes of phase I trials are typically small; some designs may lead to inaccurate estimation of the maximum tolerated dose (MTD). The objective of this study was to propose a metric assessing whether the MTD decision is sensitive to enrolling a few additional subjects in a phase I dose-finding trial. METHODS: Numerous model-based and model-assisted designs have been proposed to improve the efficiency and accuracy of finding the MTD. The Fragility Index (FI) is a widely used metric quantifying the statistical robustness of randomized controlled trials by estimating the number of events needed to change a statistically significant result to non-significant (or vice versa). We propose a modified Fragility Index (mFI), defined as the minimum number of additional participants required to potentially change the estimated MTD, to supplement existing designs identifying fragile phase I trial results. FINDINGS: Three oncology trials were used to illustrate how to evaluate the fragility of phase I trials using mFI. The results showed that two of the trials were not sensitive to additional subjects' participation while the third trial was quite fragile to one or two additional subjects. CONCLUSIONS: The mFI can be a useful metric assessing the fragility of phase I trials and facilitating robust identification of MTD.

Source: Cancers

DOI: 10.3390/cancers16203504

Authors: Amy X. Shi, Heng Zhou, Lei Nie, Lifeng Lin, Hongjian Li, Haitao Chu